Ceftriaxone-Sulbactam

# Ceftriaxone-Sulbactam ## Overview Ceftriaxone-sulbactam is a fixed-dose combination antibiotic. Ceftriaxone is a third-generation cephalosporin (beta-lactam); sulbactam is a beta-lactamase inhibitor that irreversibly inhibits certain beta-lactamases (class A TEM/SHV). This combination extends ceftriaxone’s spectrum against *Acinetobacter baumannii* and some Enterobacterales. Product ratios vary by region (commonly 1:1 or 2:1 ceftriaxone-to-sulbactam). ## Primary Indications - Complicated intra-abdominal infections - Community-acquired pneumonia - Complicated urinary tract infections (pyelonephritis) - Skin and soft tissue infections - Empiric coverage where ceftriaxone-resistant pathogens (especially *Acinetobacter* or ESBL-producing Enterobacterales) are suspected - Often used for polymicrobial infections with mixed gram-negative/aerobic-anaerobic flora ## Adult Dosing Dosing expressed as total combination dose (ceftriaxone + sulbactam). Exact local product ratio applies. - **Usual dose:** 1.5 g (1 g ceftriaxone + 0.5 g sulbactam) to 3 g (2 g + 1 g) **IV every 12 hours** - **Severe infections (e.g., *Acinetobacter* pneumonia, sepsis):** 3 g (2 g + 1 g) IV every 12 hours - **Maximum:** 6 g/day (ceftriaxone 4 g + sulbactam 2 g) per 12-hour interval - Infuse over 30-60 minutes > **Important:** Confirm local product ratio. Some formulations contain 1:1 (e.g., 1 g ceftriaxone + 1 g sulbactam per vial). Adjust doses accordingly. Dosing may differ by local susceptibility patterns and guidelines. ## Pediatric Dosing Limited published pediatric data; **consult a pediatric infectious disease specialist** for variable age and weight-based regimens. General guidance (if using a 2:1 ratio product): - **Children (≥1 month to 18 years):** 50-75 mg/kg/day (ceftriaxone component) IV divided every 12 hours, with sulbactam dosed proportionally (e.g., ~25-37.5 mg/kg/day). - **Maximum (pediatric):** 2 g/day ceftriaxone component (4 g/day total combination for 1:1 product). **Neonates (0-28 days):** Use only if no safer alternative; avoid ceftriaxone in neonates with hyperbilirubinemia or requiring calcium-containing IV solutions. Dosing: 50 mg/kg/day ceftriaxone component divided every 12-24 hours; sulbactam component adjusted proportionally—limited neonatal safety data. ## Dose Adjustments - **Renal impairment:** - Ceftriaxone is primarily hepatically cleared; sulbactam is renally excreted. - CrCl <30 mL/min: Extend sulbactam-containing dose interval to every 24 hours (maintain same total daily sulbactam exposure). - Hemodialysis: Administer after dialysis or adjust interval per protocol. - **Hepatic impairment:** No routine adjustment required for mild-moderate impairment; use caution in severe cholestasis. Combined hepatic and renal impairment: monitor accumulation. ## Contraindications - Hypersensitivity to cephalosporins, penicillins, or other beta-lactams (immediate or severe). - Neonates with hyperbilirubinemia (risk of bilirubin displacement and kernicterus). - Concomitant IV calcium in neonates (≤28 days) due to precipitation risk (ceftriaxone-calcium crystals). ## Adverse Effects - **Common:** Diarrhea, injection site pain, elevated liver enzymes - **Serious:** - Ceftriaxone: Biliary pseudolithiasis, hemolytic anemia (rare), anaphylaxis, C. difficile colitis - Sulbactam component: thrombocytopenia, hypersensitivity (rare) - **Ceftriaxone-specific:** Prolonged PT/INR possible (vitamin K responsive); avoid in hyperbilirubinemic neonates ## Key Drug Interactions - **Calcium-containing IV solutions:** Contraindicated in neonates ≤28 days (ceftriaxone precipitation); separate by at least 48 hours in older patients. - **Warfarin:** Enhanced anticoagulant effect (monitor INR). - **Live bacterial vaccines:** Avoid within 3 days of antibiotic use. - **Cholestyramine / colestipol:** Reduced absorption (administer at least 2 hours apart). ## Monitoring - Baseline: Renal and hepatic function, CBC with differential, coagulation profile (especially if prolonged therapy or malnourished). - Periodic: CBC, renal function (sulbactam clearance), signs of C. difficile diarrhea, PT/INR (vitamin K deficiency risk). - Therapeutic response: Clinical signs (fever, WBC, cultures). ## Clinical Pearls - Ceftriaxone-sulbactam provides a broader spectrum than ceftriaxone alone via sulbactam’s beta-lactamase inhibition, including enhanced activity against *Acinetobacter baumannii*. - Sulbactam also has weak intrinsic activity against *Acinetobacter*—not to be confused with high-dose ampicillin-sulbactam regimens. - Avoid concurrent IV calcium in neonates; in older patients, separate ceftriaxone infusion and calcium-containing fluids by ≥48 hours. - Biliary sludging is a known effect with ceftriaxone; use caution in patients with gallbladder disease. - Use weight-based doses per 2:1 ratio product where possible; fixed dosing less evidence-based. **Disclaimer:** This information is for educational purposes only. Always verify dosing, local resistance patterns, and prescribing information specific to your region. Consult a clinical pharmacist or drug reference for individual patient use.